Paper3720176
Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration.
Kleinbloesem CH and 5 others. Clin Pharmacol Ther, 1986. Cited by 105 papers, by iCite.
Cite this record
ConductScience Library. Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis after intravenous and oral administration. Papers, record 3720176. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3720176
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Blood Pressure | Major topic |
| Liver Cirrhosis | Major topic |
| Nifedipine | Major topic |
| Absorption | |
| Administration, Oral | |
| Adult | |
| Aged | |
| Female | |
| Half-Life | |
| Heart Rate | |
| Humans | |
| Infusions, Parenteral | |
| Kinetics | |
| Male | |
| Middle Aged |
Source PubMed
Cited by39
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 105 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41499374 | Using Physiologically Based Pharmacokinetic Modeling and Simulations to Predict Antihypertensive Drug Doses in Cirrhotic Patients. | J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/41499374 | PubMed |
| 40614122 | Pharmacokinetics of Belumosudil and Its Metabolites in Individuals With Hepatic Impairment. | Clin Transl Sci | 2025 | https://conductscience.org/library/papers/40614122 | PubMed |
| 34272705 | Sources of Interindividual Variability. | Methods Mol Biol | 2021 | https://conductscience.org/library/papers/34272705 | PubMed |
| 33163829 | Improving Medication-Related Outcomes in Chronic Liver Disease. | Hepatol Commun | 2020 | https://conductscience.org/library/papers/33163829 | PubMed |
| 31112623 | Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study. | Br J Clin Pharmacol | 2019 | https://conductscience.org/library/papers/31112623 | PubMed |
| 30052269 | Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib. | J Clin Pharmacol | 2018 | https://conductscience.org/library/papers/30052269 | PubMed |
| 27519334 | Disposition, Elimination and Haemodynamic Effects of Gallopamil in Patients with Fatty Liver Disease. | Clin Drug Investig | 1995 | https://conductscience.org/library/papers/27519334 | PubMed |
| 27203676 | Significant change of cytochrome P450s activities in patients with hepatocellular carcinoma. | Oncotarget | 2016 | https://conductscience.org/library/papers/27203676 | PubMed |
| 27106837 | Effect of Gastric Fluid Volume on the In Vitro Dissolution and In Vivo Absorption of BCS Class II Drugs: a Case Study with Nifedipine. | AAPS J | 2016 | https://conductscience.org/library/papers/27106837 | PubMed |
| 26070946 | A Prediction Model of Drug Exposure in Cirrhotic Patients According to Child-Pugh Classification. | Clin Pharmacokinet | 2015 | https://conductscience.org/library/papers/26070946 | PubMed |
| 21394568 | The management of hypertensive emergencies in children after stem cell transplantation. | Int J Clin Pharm | 2011 | https://conductscience.org/library/papers/21394568 | PubMed |
| 19212316 | Reduced duodenal cytochrome P450 3A protein expression and catalytic activity in patients with cirrhosis. | Clin Pharmacol Ther | 2009 | https://conductscience.org/library/papers/19212316 | PubMed |
| 18762933 | Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. | Eur J Clin Pharmacol | 2008 | https://conductscience.org/library/papers/18762933 | PubMed |
| 16718615 | CYP induction-mediated drug interactions: in vitro assessment and clinical implications. | Pharm Res | 2006 | https://conductscience.org/library/papers/16718615 | PubMed |
| 15924505 | Dose adjustment in patients with liver disease. | Drug Saf | 2005 | https://conductscience.org/library/papers/15924505 | PubMed |
| 12036393 | Use of sensitivity functions to characterise and compare the forgiveness of drugs. | Clin Pharmacokinet | 2002 | https://conductscience.org/library/papers/12036393 | PubMed |
| 11785692 | Differentiation of gut and hepatic first-pass effect of drugs: 1. Studies of verapamil in ported dogs. | Pharm Res | 2001 | https://conductscience.org/library/papers/11785692 | PubMed |
| 10589374 | Effects of liver disease on pharmacokinetics. An update. | Clin Pharmacokinet | 1999 | https://conductscience.org/library/papers/10589374 | PubMed |
| 9820880 | Effect of hepatic insufficiency on pharmacokinetics and drug dosing. | Pharm World Sci | 1998 | https://conductscience.org/library/papers/9820880 | PubMed |
| 9258630 | Drug administration in chronic liver disease. | Drug Saf | 1997 | https://conductscience.org/library/papers/9258630 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/3720176
GET https://conductscience.org/api/papers/v1/3720176/cited_by?page=2